ARCHIVES

Congressional Committee, SEC Probe ImClone’s Statements To Shareholders.

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

Increase In DCCR Grants May Not Be Possible Without Decreasing Quality, Committee Told

July 28, 1978

House subcommittee’s 5.6% Increase For NIH includes $2.5 Billion for NCI

July 18, 1997

FDA Names Director Of New Center For Tobacco Products

September 11, 2009

Center Core Grant Guidelines Changes Approved By NCAB

February 13, 1981

In Brief: DeVita On Laetrile Hit List; Hammer Removal As Panel Head Sought By Love Canal Activist

November 6, 1981

Chemical Distribution To Grantees Delayed while HEW Considers Charging For It

June 22, 1979